Holen Sie sich die Stockscreener-App
1.20
0.84%
0.01
Handel nachbörslich:
1.20
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
Dyne Therapeutics Announces Positive Topline Results from - GlobeNewswire
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - MarketScreener
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
Protara (Nasdaq: TARA) Sees 100% Success in TARA-002 Pediatric LM Phase 2 Study - Stock Titan
Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women's Health - PR Newswire
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis - Business Wire
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - GlobeNewswire
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis - GlobeNewswire
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRCSlideshow (NASDAQ:XLO) 2025-11-11 - Seeking Alpha
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - Yahoo Finance
Intellia Therapeutics Presents Positive Pooled Phase 1/2 - GlobeNewswire
Cadrenal Therapeutics, Inc. - TradingView
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for - GlobeNewswire
Viking Therapeutics, Inc. (VKTX) Stock: Jumps as New Obesity Drug Data Shows Strong Metabolic Improvements - parameter.io
Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites - Stock Titan
Beam Therapeutics to Present Updated Data from BEACON Phase - GlobeNewswire
2,541,781 Restricted Stock Units of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PR Newswire
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewswire
Intensity Therapeutics surges 395% on phase 1/2 data for solid tumors asset - Seeking Alpha
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - Yahoo Finance
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - GlobeNewswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to - GlobeNewswire
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules - Business Wire
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics
BlossomHill Therapeutics Presents Preliminary Findings from - GlobeNewswire
Tango Therapeutics Reports Positive Data from Ongoing Phase - GlobeNewswire
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - Yahoo Finance
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 - Yahoo Finance
Perspective Therapeutics Reports 44% ORR in Cohort 2 | CATX Stock News - Stock Titan
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) - The Manila Times
RAPT Therapeutics to Report Topline Data from Phase 2 - GlobeNewswire
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting - Yahoo Finance
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - BioSpace
Monopar Therapeutics Inc. Announces Oral Presentation at AASLD 2025 for Phase 2 Study on Tiomolybdate Choline in Wilson Disease - Quiver Quantitative
Tvardi Therapeutics, Inc. Updates on Phase 2 REVERT Trial Results - TradingView
Denali Therapeutics Announces FDA Review Extension of BLA - GlobeNewswire
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewswire
Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round - Business Wire
Verrica Pharmaceuticals to Present New Data on VP-315 from - GlobeNewswire
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Viking Therapeutics Stock: A Speculative Buy (NASDAQ:VKTX) - Seeking Alpha
Cellphire Therapeutics announces CRYPTICS Phase 2/3 Clinical Study Final Topline Results - GlobeNewswire
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension - GlobeNewswire
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Business Wire
Viking Therapeutics: Overdue For Gains (NASDAQ:VKTX) - Seeking Alpha
United Therapeutics (UTHR) Phase 3 TETON-2 Results Slideshow (NASDAQ:UTHR) 2025-09-28 - Seeking Alpha
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial - MSN
UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic - GlobeNewswire
Phase 2 Colorectal Cancer Trial Results: Leap Therapeutics' Sirexatamab Study Data Coming at ESMO 2025 - Stock Titan
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):